Finally, early preclinical studies suggested that combining a pan-PI3K inhibitor with an immune adjuvant induces production of IFNγ and IL-17-producing inflammatory T cells, leading to profound anti-tumorigenic immune responses in mouse models of lung cancer and melanoma, paving the way for future studies looking at combination therapy with immunotherapies [135]. The gene discussed is PIK3CD; the disease is melanoma.